Cartagena Protocol on Biosafety: Compliance and LMO Transfer Guide

The Cartagena Protocol on Biosafety to the Convention on Biological Diversity is an international treaty governing the cross-border transfer, transit, handling, and use of living modified organisms (LMOs) resulting from modern biotechnology. Adopted in 2000 and entering into force in 2003, the agreement establishes procedural mechanisms to prevent adverse effects on biological diversity and human health. For life sciences researchers, compliance with the protocol governs how genetically modified biological materials are transferred across international borders.

What it is and who runs it

The Cartagena Protocol on Biosafety operates as a supplementary agreement to the Convention on Biological Diversity (CBD). It is administered by the Secretariat of the Convention on Biological Diversity (SCBD) in Montreal, Canada. Its governing body is the Conference of the Parties serving as the meeting of the Parties to the Protocol (COP-MOP), which governs the Protocol.

The central operational platform of the treaty is the Biosafety Clearing-House (BCH), an online information portal established under Article 20. The BCH houses national biosafety laws, registers of Competent National Authorities (CNAs), national focal points, and risk assessment records. In research practice, work in biology increasingly involves international collaboration, making standardized biosafety oversight critical when modified strains cross borders.

Eligibility (summary, with the official source)

As described in the Protocol text and on the Secretariat’s biosafety page (checked 2026-11-07), the protocol covers living modified organisms that may have adverse effects on the conservation and sustainable use of biological diversity, taking into account risks to human health. Under Article 3, a living modified organism is any living organism that possesses a novel combination of genetic material obtained through the use of modern biotechnology. A living organism is any biological entity capable of transferring or replicating genetic material, and modern biotechnology covers in vitro nucleic acid techniques and cell fusion beyond the taxonomic family.

The protocol establishes three distinct operational tracks:

• Intentional Introduction into the Environment: Field trials and environmental releases require the full Advance Informed Agreement (AIA) procedure under Articles 7 through 10.
• Contained Laboratory Use: Under Article 6, transboundary movements of LMOs destined for contained laboratory facilities are excluded from the AIA procedure, provided the transfer complies with importing country standards. National import permits and Article 18 shipping documents remain mandatory.
• Direct Use as Food, Feed, or Processing (LMO-FFP): Governed by Article 11, under which a Party that authorizes domestic use informs the Parties through the BCH.

Non-Party states are not exempt from destination controls: Article 24 provides that transboundary movements between Parties and non-Parties must be consistent with the objective of the Protocol, so a researcher based in a non-Party country should still expect to meet the importing country’s biosafety requirements.

What it funds or requires

The protocol does not provide direct research grant funding; rather, it establishes binding statutory compliance obligations for researchers, institutions, and governments:

• Advance Notification (Article 8 & Annex I): The Party of export, or the exporter, must notify the importing Party’s competent national authority before the first intentional transboundary movement of LMOs for introduction into the environment, with at least the information listed in Annex I (including taxonomic status, characteristics of the organism and modification, intended use and a risk assessment report).
• Scientific Risk Assessment (Article 15 & Annex III): Risk assessments underpinning import decisions must be carried out in a scientifically sound manner, as set out in Annex III, in line with priorities in conservation biology.
• Handling and Identification (Article 18): LMOs must be handled, packaged and transported under conditions of safety, and accompanying documentation must identify them as living modified organisms and give a contact point. Where a transfer involves a research partner, terms are often coordinated through a material transfer agreement.
• Competent Authority Authorization: Under Article 10, the importing Party decides whether the movement may proceed only after its written consent or after at least ninety days without a subsequent written consent, as it tells the notifier.

Application or compliance steps

To transfer or import living modified organisms internationally, researchers should follow this compliance workflow:

1. Classify the Material: Determine whether the organism qualifies as an LMO under Article 3. Only living organisms with a novel combination of genetic material obtained through modern biotechnology fall within the definition.
2. Select the Regulatory Route: Identify whether the transfer is for contained research (Article 6) or intentional environmental release (Article 7).
3. Search the Biosafety Clearing-House: Check the BCH at https://bch.cbd.int/ to identify the importing country’s competent national authority, national focal point, and national biosafety requirements.
4. Assemble Application Dossiers: Prepare the required domestic import permit application or the comprehensive Annex I dossier. Research councils such as the BBSRC fund biological research, but the Protocol itself sets no funding rules; check your institution’s biosafety office for local sign-off.
5. Await Formal CNA Approval: Obtain written clearance from the destination authority before initiating dispatch.
6. Package and Label per Article 18: Handle, package and transport the material under conditions of safety, taking into account relevant international rules and standards, and make sure accompanying documents identify the LMOs, state any handling, storage, transport and use requirements, and give a contact point.

Typical timeline phases (no calendar dates as facts)

Statutory transfers subject to the Advance Informed Agreement procedure proceed through standardized administrative phases:

• Phase 1: Dossier Preparation: Exporters compile the Annex I information and the risk assessment report.
• Phase 2: Formal Notification: The exporter submits the formal notification to the importing Party’s CNA.
• Phase 3: Statutory Acknowledgement: Under Article 9, the importing CNA must acknowledge receipt in writing within 90 days.
• Phase 4: Risk Review: The importing Party assesses the notification, with decisions taken in accordance with Article 15 on risk assessment.
• Phase 5: Decision Communication: Under Article 10, where consent is required, the importing Party must communicate its written decision within 270 days of receiving the notification (approving the import with or without conditions, prohibiting it, or requesting additional information).
• Phase 6: Transport: The shipment moves with the Article 18 documentation.

Common mistakes

Researchers commonly encounter regulatory delays due to several recurring errors:

• Assuming Contained Use Means Zero Regulation: While contained laboratory research is exempt from the AIA procedure, national import permits and Article 18 documentation remain mandatory.
• Confusing the Cartagena Protocol with Nagoya: Cartagena regulates biosafety and LMOs, whereas the Nagoya Protocol governs Access and Benefit-Sharing (ABS) for genetic resources.
• Omitting Article 18 Declarations: Article 18 requires accompanying documentation to identify the material as living modified organisms and give a contact point.
• Assuming Non-Party Exporter Exemption: Under Article 24, movements involving non-Parties must still be consistent with the Protocol’s objective, and importing countries apply their own biosafety rules.
• Underestimating Precautionary Decisions: Under Article 10.6, lack of scientific certainty does not prevent an authority from restricting or prohibiting an LMO import.

Related programs

The Cartagena Protocol operates alongside other key international instruments governing biological materials:

Framework / Instrument	Governing Body	Primary Scope	Key Compliance Mechanism	Relevance to Research Labs
Cartagena Protocol on Biosafety	Secretariat of the CBD	Transboundary transfer and safe handling of LMOs	Advance Informed Agreement (AIA), BCH registry, Article 18 shipping declarations	Governs cross-border transfers of recombinant strains, cell lines, and transgenic organisms
Nagoya Protocol on Access and Benefit-Sharing	Secretariat of the CBD	Fair and equitable sharing of benefits from genetic resources	Prior Informed Consent (PIC), Mutually Agreed Terms (MAT), ABS Clearing-House	Applies when collecting, sequencing, or utilizing native genetic resources
Convention on Biological Diversity (CBD)	Parties to the CBD (Secretariat in Montreal)	Conservation and sustainable use of global biodiversity	National Biodiversity Strategies, COP decisions, multilateral conservation targets	Parent convention under which the Cartagena Protocol was adopted
WTO SPS Agreement	World Trade Organization	Trade measures protecting human, animal, and plant life	Science-based risk assessment, international standards harmonization	Ensures national biosafety import controls do not form arbitrary trade barriers
International Plant Protection Convention (IPPC)	Food and Agriculture Organization (FAO)	Prevention of plant pest and pathogen introduction	Phytosanitary certificates, ISPM international standards	Phytosanitary requirements may apply when moving plants and seed stocks

FAQ

What is the difference between an LMO and a GMO under the Cartagena Protocol?

Under the protocol, a “living modified organism” (LMO) is any biological entity capable of transferring or replicating genetic material that possesses a novel combination of genetic material obtained through modern biotechnology. “GMO” is the broader everyday term; the Protocol’s own defined term, and the scope of its procedures, is the living modified organism.

Does the Cartagena Protocol apply to academic laboratories conducting contained research?

Article 6 excludes the transboundary movement of LMOs destined for contained use, undertaken in accordance with the standards of the Party of import, from the AIA procedure. The importing Party keeps the right to set its own standards for contained use, and Article 18 requires accompanying documentation that identifies the LMOs, so check the importing country’s national requirements.

How do researchers identify the Competent National Authority for an importing country?

Search the Biosafety Clearing-House at https://bch.cbd.int/, the Protocol’s portal for information on national laws, focal points and competent national authorities. Each Party designates these under Article 19.

What documentation must accompany an international LMO shipment?

Under Article 18, documentation for LMOs destined for contained use must clearly identify them as living modified organisms, specify any requirements for safe handling, storage, transport and use, and give a contact point, including the name and address of the individual and institution to which they are consigned.

Sources

• Secretariat of the Convention on Biological Diversity (SCBD). (2000). Cartagena Protocol on Biosafety to the Convention on Biological Diversity: Text and Annexes. https://www.cbd.int/doc/legal/cartagena-protocol-en.pdf (checked 2026-11-07).
• Secretariat of the Convention on Biological Diversity (SCBD). (2026). The Biosafety Clearing-House (BCH) Portal. https://bch.cbd.int/ (checked 2026-11-07).
• Secretariat of the Convention on Biological Diversity (SCBD). (2026). Cartagena Protocol on Biosafety Overview. https://www.cbd.int/biosafety/ (checked 2026-11-07).